Hot update bolstered Supernus Pharmaceuticals (SUPN) stock in the After hours

SFT Stock
SFT Stock

In after-hours trade Tuesday, Supernus Pharmaceuticals (SUPN) shares soared more than ‎‎24% percent to $27.99, following the firm revealed promising findings from a trial of its new ‎treatment for attention deficit hyperactivity disorder, or ADHD. Supernus reported Tuesday ‎afternoon that its intended goal was met in a phase 3 trial of the medication, known as SPN-‎‎812, in adults. ‎

Get the hottest stocks to trade every day ‎before the market opens 100% ‎free. Click here now. 

‎The Food and Drug Administration is actively reviewing the drug for use in children aged 6 ‎to 17, and once it is approved by the FDA, Supernus plans to ask that the drug be considered ‎for adults as well. ‎

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Shares surged more than 40% as trades resumed after the end of after-hours trading ‎Tuesday afternoon, but gradually declined to around 20 percentsurge by the end of the ‎extended session.‎

Read More


Please enter your comment!
Please enter your name here